Literature DB >> 35606653

Fine mapping and candidate gene analysis of a dravet syndrome modifier locus on mouse chromosome 11.

Jennifer A Kearney1, Letonia D Copeland-Hardin2, Samantha Duarte3, Nicole A Zachwieja3, Isaiah K Eckart-Frank3, Nicole A Hawkins3.   

Abstract

Pathogenic variants in SCN1A result in a spectrum of phenotypes ranging from mild febrile seizures to Dravet syndrome, a severe infant-onset epileptic encephalopathy. Individuals with Dravet syndrome have developmental delays, elevated risk for sudden unexpected death in epilepsy (SUDEP), and have multiple seizure types that are often refractory to treatment. Although most Dravet syndrome variants arise de novo, there are cases where an SCN1A variant was inherited from mildly affected parents, as well as some individuals with de novo loss-of-function or truncation mutations that presented with milder phenotypes. This suggests that disease severity is influenced by other factors that modify expressivity of the primary mutation, which likely includes genetic modifiers. Consistent with this, the Scn1a+/- mouse model of Dravet syndrome exhibits strain-dependent variable phenotype severity. Scn1a+/- mice on the 129S6/SvEvTac (129) strain have no overt phenotype and a normal lifespan, while [C57BL/6Jx129]F1.Scn1a+/- mice have severe epilepsy with high rates of premature death. Low resolution genetic mapping identified several Dravet syndrome modifier (Dsm) loci responsible for the strain-dependent difference in survival of Scn1a+/- mice. To confirm the Dsm5 locus and refine its position, we generated interval-specific congenic strains carrying 129-derived chromosome 11 alleles on the C57BL/6J strain and localized Dsm5 to a 5.9 Mb minimal region. We then performed candidate gene analysis in the modifier region. Consideration of brain-expressed genes with expression or coding sequence differences between strains along with gene function suggested numerous strong candidates, including several protein coding genes and two miRNAs that may regulate Scn1a transcript.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35606653     DOI: 10.1007/s00335-022-09955-y

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   3.224


  43 in total

1.  Multicenter prospective longitudinal study in 34 patients with Dravet syndrome: Neuropsychological development in the first six years of life.

Authors:  Domenica Battaglia; Daniela Chieffo; Simona Lucibello; Carla Marini; Valentina Sibilia; Davide Mei; Francesca Darra; Francesca Offredi; Elena Fontana; Nicola Specchio; Simona Cappelletti; Tiziana Granata; Francesca Ragona; Mara Patrini; Maria G Baglietto; Giulia Prato; Annarita Ferrari; Federico Vigevano; Eugenio Mercuri; Bernardo Dalla Bernardina; Renzo Guerrini; Charlotte Dravet; Francesco Guzzetta
Journal:  Brain Dev       Date:  2021-01-18       Impact factor: 1.961

2.  Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome.

Authors:  Christel Depienne; Oriane Trouillard; Isabelle Gourfinkel-An; Cécile Saint-Martin; Delphine Bouteiller; Denis Graber; Marie-Anne Barthez-Carpentier; Agnès Gautier; Nathalie Villeneuve; Charlotte Dravet; Marie-Odile Livet; Clothilde Rivier-Ringenbach; Claude Adam; Sophie Dupont; Stéphanie Baulac; Delphine Héron; Rima Nabbout; Eric Leguern
Journal:  J Med Genet       Date:  2010-06       Impact factor: 6.318

Review 3.  Dravet syndrome (severe myoclonic epilepsy in infancy).

Authors:  Charlotte Dravet; Hirokazu Oguni
Journal:  Handb Clin Neurol       Date:  2013

4.  The location and type of mutation predict malformation severity in isolated lissencephaly caused by abnormalities within the LIS1 gene.

Authors:  C Cardoso; R J Leventer; N Matsumoto; J A Kuc; M B Ramocki; S K Mewborn; L L Dudlicek; L F May; P L Mills; S Das; D T Pilz; W B Dobyns; D H Ledbetter
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

Review 5.  The core Dravet syndrome phenotype.

Authors:  Charlotte Dravet
Journal:  Epilepsia       Date:  2011-04       Impact factor: 5.864

6.  Impaired nociception and pain sensation in mice lacking the capsaicin receptor.

Authors:  M J Caterina; A Leffler; A B Malmberg; W J Martin; J Trafton; K R Petersen-Zeitz; M Koltzenburg; A I Basbaum; D Julius
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

7.  Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients.

Authors:  C Depienne; O Trouillard; C Saint-Martin; I Gourfinkel-An; D Bouteiller; W Carpentier; B Keren; B Abert; A Gautier; S Baulac; A Arzimanoglou; C Cazeneuve; R Nabbout; E LeGuern
Journal:  J Med Genet       Date:  2008-10-17       Impact factor: 6.318

8.  Neuron-glia signaling in developing retina mediated by neurotransmitter spillover.

Authors:  Juliana M Rosa; Rémi Bos; Georgeann S Sack; Cécile Fortuny; Amit Agarwal; Dwight E Bergles; John G Flannery; Marla B Feller
Journal:  Elife       Date:  2015-08-14       Impact factor: 8.140

9.  Diagnostic implications of genetic copy number variation in epilepsy plus.

Authors:  Antonietta Coppola; Elena Cellini; Hannah Stamberger; Elmo Saarentaus; Valentina Cetica; Dennis Lal; Tania Djémié; Magdalena Bartnik-Glaska; Berten Ceulemans; J Helen Cross; Tine Deconinck; Salvatore De Masi; Thomas Dorn; Renzo Guerrini; Dorotha Hoffman-Zacharska; Frank Kooy; Lieven Lagae; Nicholas Lench; Johannes R Lemke; Ersilia Lucenteforte; Francesca Madia; Heather C Mefford; Deborah Morrogh; Peter Nuernberg; Aarno Palotie; An-Sofie Schoonjans; Pasquale Striano; Elzbieta Szczepanik; Anna Tostevin; Joris R Vermeesch; Hilde Van Esch; Wim Van Paesschen; Jonathan J Waters; Sarah Weckhuysen; Federico Zara; Peter De Jonghe; Sanjay M Sisodiya; Carla Marini
Journal:  Epilepsia       Date:  2019-03-13       Impact factor: 5.864

10.  Modifier genes in SCN1A-related epilepsy syndromes.

Authors:  Iris M de Lange; Flip Mulder; Ruben van 't Slot; Anja C M Sonsma; Marjan J A van Kempen; Isaac J Nijman; Robert F Ernst; Nine V A M Knoers; Eva H Brilstra; Bobby P C Koeleman
Journal:  Mol Genet Genomic Med       Date:  2020-02-07       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.